Global Bcr-Abl Inhibitor Market, Drug Sales & Clinical Trials Insight 2028
Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.
Global Bcr-Abl Inhibitor Market, Drug Sales & Clinical Trials Insight 2028 Report Highlights:
Imatinib was first Bcr-Abl inhibitor, which was approved by FDA in 2001 as first-line therapy for chronic myeloid leukemia. Unfortunately, the appearance of resistance phenomena required the development of a second generation of Bcr-Abl inhibitors. Currently three 2nd generation drugs including Nilotinib, Dasatinib and Bosulitinib whereas one 3rd generation drug, Ponatinib has been approved for the management of CML which have shown enhanced efficacy in comparison to already approved drugs. In addition, Olverembatinib which is third generation inhibitor developed by Ascentage Pharma has gained entry into China. The promising response of Bcr-Abl inhibitors in the market has propelled the further research and development activities in this domain.
Companies operating in the Bcr-Abl tyrosine kinase inhibitors industry are focusing on increasing their geographic presence by means of strategic acquisitions and collaborations with leading players and increasing FDA approvals of therapeutic drugs in their respective domains and geographies. For instance, Ascentage Pharma also announced a multifaced strategic collaboration with Innovent Biologics. This collaboration includes the joint clinical development and commercialization of Olverembatinib in China. Ascentage Pharma has recently announced that the Center for Drug Evaluation (CDE) of China National Medical Products Administration (NMPA) has granted approval to Olverembatinib (HQP1351), for the treatment of patients with chronic phase CML resistant and/intolerant to first and second generation TKI.
US has been dominating the global Bcr-Abl inhibitor market driven by more than 100 clinical trials which are evaluating the role of novel Bcr-Abl inhibitors as monotherapy or combinational therapy in wide range of therapeutic indications. Further, the governments regulatory are also increasingly granting special designations such as orphan drug, breakthrough therapy, and others which promote the research and development. For instance in 2020, US FDA granted HQP1351 orphan drug designation for the treatment of patients with chronic myeloid leukemia. HQP1351 is a novel, orally active, potent third generation Bcr-Abl inhibitor which is designed to target Bcr-Abl mutants, including T3151.
As per our report findings, the global Bcr-Abl inhibitor market will surpass US$ 8 Billion by 2028. The major factor attributing to the growth of the market is increasing prevalence of chronic myeloid leukemia (CML). Furthermore, growing investments in research and development programs by biotechnology and pharmaceutical companies are also boosting the market growth. The development of favorable reimbursement policies and introduction of generics in the market will also drive the growth of market. The key companies in global Bcr-Abl inhibitor market are Ascentage Pharma, Incyte Pharmaceuticals, Novartis, Bristol Meyer Squibb, Ariad Pharmaceuticals, and others.
Our report provides in-depth analysis on the available Bcr-Abl inhibitors in the global market along with their commercial information. In addition, insights into ongoing clinical trials and key drugs in research and development are also included in the report. The report also provides profiles of leading players operating in the global tyrosine kinase inhibitors market. The report includes detailed analysis on market dynamics, market estimation and forecast for the period of 2022 to 2028. The report segments market on the basis of drug type and geographies.
Global Bcr-Abl Inhibitor Market, Drug Sales & Clinical Trials Insight 2028 Report Highlights:
- Global Bcr-Abl Inhibitor Market Opportunity > USD 8 Billion
- Approved Bcr-Abl Inhibitor Drugs: 8 Drugs
- Global Bcr-Abl Inhibitor Market Regional Analysis & Forecast Till 2028
- Bcr-Abl Inhibitor Drug Market Past Sales & Future Forecast Till 2028
- Market Analysis By First, Second & Third Generation Approved drugs
- Bcr-Abl Inhibitor Drug Prices, Dosage & Patent Insight
- Global Bcr-Abl Inhibitor Drug clinical Trials Insight by Indication ,Company, County & Phase
Imatinib was first Bcr-Abl inhibitor, which was approved by FDA in 2001 as first-line therapy for chronic myeloid leukemia. Unfortunately, the appearance of resistance phenomena required the development of a second generation of Bcr-Abl inhibitors. Currently three 2nd generation drugs including Nilotinib, Dasatinib and Bosulitinib whereas one 3rd generation drug, Ponatinib has been approved for the management of CML which have shown enhanced efficacy in comparison to already approved drugs. In addition, Olverembatinib which is third generation inhibitor developed by Ascentage Pharma has gained entry into China. The promising response of Bcr-Abl inhibitors in the market has propelled the further research and development activities in this domain.
Companies operating in the Bcr-Abl tyrosine kinase inhibitors industry are focusing on increasing their geographic presence by means of strategic acquisitions and collaborations with leading players and increasing FDA approvals of therapeutic drugs in their respective domains and geographies. For instance, Ascentage Pharma also announced a multifaced strategic collaboration with Innovent Biologics. This collaboration includes the joint clinical development and commercialization of Olverembatinib in China. Ascentage Pharma has recently announced that the Center for Drug Evaluation (CDE) of China National Medical Products Administration (NMPA) has granted approval to Olverembatinib (HQP1351), for the treatment of patients with chronic phase CML resistant and/intolerant to first and second generation TKI.
US has been dominating the global Bcr-Abl inhibitor market driven by more than 100 clinical trials which are evaluating the role of novel Bcr-Abl inhibitors as monotherapy or combinational therapy in wide range of therapeutic indications. Further, the governments regulatory are also increasingly granting special designations such as orphan drug, breakthrough therapy, and others which promote the research and development. For instance in 2020, US FDA granted HQP1351 orphan drug designation for the treatment of patients with chronic myeloid leukemia. HQP1351 is a novel, orally active, potent third generation Bcr-Abl inhibitor which is designed to target Bcr-Abl mutants, including T3151.
As per our report findings, the global Bcr-Abl inhibitor market will surpass US$ 8 Billion by 2028. The major factor attributing to the growth of the market is increasing prevalence of chronic myeloid leukemia (CML). Furthermore, growing investments in research and development programs by biotechnology and pharmaceutical companies are also boosting the market growth. The development of favorable reimbursement policies and introduction of generics in the market will also drive the growth of market. The key companies in global Bcr-Abl inhibitor market are Ascentage Pharma, Incyte Pharmaceuticals, Novartis, Bristol Meyer Squibb, Ariad Pharmaceuticals, and others.
Our report provides in-depth analysis on the available Bcr-Abl inhibitors in the global market along with their commercial information. In addition, insights into ongoing clinical trials and key drugs in research and development are also included in the report. The report also provides profiles of leading players operating in the global tyrosine kinase inhibitors market. The report includes detailed analysis on market dynamics, market estimation and forecast for the period of 2022 to 2028. The report segments market on the basis of drug type and geographies.
1. INTRODUCTION TO BCR-ABL INHIBITORS
1.1 Overview
1.2 Evolution of Bcr-Abl Inhibitors
2. BCR-ABL INHIBITOR - MECHANISM OF ACTION
2.1 Overview
2.2 Role of Bcr-Abl Inhibitor in Cancer
3. GLOBAL BCR-ABL INHIBITOR DRUG MARKET INSIGHT
3.1 Current Market Scenario
3.2 Future Market Opportunity
4. BCR-ABL INHIBITOR DRUG MARKET REGIONAL ANALYSIS
4.1 US
4.2 Europe
4.3 Japan
4.4 Rest of World
5. BCR-ABL INHIBITOR DRUG MARKET BY PRODUCT
5.1 First Generation Bcr-Abl Inhibitor
5.2 Second Generation Bcr-Abl Inhibitor
5.3 Third Generation Bcr-Abl Inhibitor
6. IMATINIB – 1ST GENERATION BCR-ABL INHIBITOR 2001
6.1 Overview
6.2 Patent & Exclusivity
6.3 Pricing & Dosage Analysis
6.3.1 Branded
6.3.2 Generic
6.4 Sales Analysis
7. DASATINIB – 2ND GENERATION BCR-ABL INHIBITOR 2006
7.1 Overview
7.2 Patent & Exclusivity
7.3 Pricing & Dosage Analysis
7.3.1 Branded
7.3.2 Generic
7.4 Sales Analysis
8. NILOTINIB – 2ND GENERATION BCR-ABL INHIBITOR 2007
8.1 Overview
8.2 Patent & Exclusivity
8.3 Price & Dosage Analysis
8.4 Sales Analysis
9. BOSUTINIB – 2ND GENERATION BCR-ABL INHIBITOR 2012
9.1 Overview
9.2 Patent & Exclusivity
9.3 Pricing & Dosage Analysis
9.4 Sales Analysis
10. PONATINIB – 3RD GENERATION BCR-ABL INHIBITOR 2012
10.1 Overview
10.2 Patent & Exclusivity
10.3 Pricing & Dosage Analysis
10.4 Sales Analysis
11. ASCIMINIB – 3RD GENERATION BCR-ABL INHIBITOR 2021
11.1 Overview
11.2 Patent & Exclusivity
11.3 Pricing & Dosage Analysis
12. OLVEREMBATINIB – 3RD GENERATION BCR-ABL INHIBITOR 2021
13. BCR-ABL INHIBITORS SALES FORECAST 2022 TILL 2028
13.1 Gleevec/Glivec Sales Forecast
13.2 Sprycel Sales Forecast
13.3 Tasigna Sales Forecast
13.4 Bosulif Sales Forecast
13.5 Iclusig Sales Forecast
14. BCR-ABL INHIBITOR MARKET CLINICAL TRIAL INSIGHTS
14.1 By Indication
14.2 By Organization
14.3 By Patient Segment
14.4 By Phase
14.5 By Status
14.6 By Region
15. GLOBAL BCR-ABL TYROSINE KINASE INHIBITORS CLINICAL TRIALS INSIGHT BY COMPANY, INDICATION & PHASE
15.1 Preclinical
15.2 Clinical
15.3 Phase-I
15.4 Phase-I/II
15.5 Phase-II
15.6 Phase-II/III
15.7 Registered
16. MARKETED BCR-ABL INHIBITORS CLINICAL TRIALS INSIGHT
17. BCR-ABL INHIBITORS MARKET DYNAMICS
17.1 Market Favorable Parameters
17.2 Market Challenges
18. BCR-ABL INHIBITOR MARKET FUTURE PERSPECTIVE
19. COMPETITIVE LANDSCAPE
19.1 Ascentage Pharma
19.2 AstraZeneca
19.3 Bristol Myers Squibb
19.4 Fusion Pharmaceuticals
19.5 Incyte Pharmaceutical
19.6 Merck
19.7 Novartis
19.8 Pfizer
19.9 Takeda Pharmaceuticals
19.10 Teva Pharmaceutical
1.1 Overview
1.2 Evolution of Bcr-Abl Inhibitors
2. BCR-ABL INHIBITOR - MECHANISM OF ACTION
2.1 Overview
2.2 Role of Bcr-Abl Inhibitor in Cancer
3. GLOBAL BCR-ABL INHIBITOR DRUG MARKET INSIGHT
3.1 Current Market Scenario
3.2 Future Market Opportunity
4. BCR-ABL INHIBITOR DRUG MARKET REGIONAL ANALYSIS
4.1 US
4.2 Europe
4.3 Japan
4.4 Rest of World
5. BCR-ABL INHIBITOR DRUG MARKET BY PRODUCT
5.1 First Generation Bcr-Abl Inhibitor
5.2 Second Generation Bcr-Abl Inhibitor
5.3 Third Generation Bcr-Abl Inhibitor
6. IMATINIB – 1ST GENERATION BCR-ABL INHIBITOR 2001
6.1 Overview
6.2 Patent & Exclusivity
6.3 Pricing & Dosage Analysis
6.3.1 Branded
6.3.2 Generic
6.4 Sales Analysis
7. DASATINIB – 2ND GENERATION BCR-ABL INHIBITOR 2006
7.1 Overview
7.2 Patent & Exclusivity
7.3 Pricing & Dosage Analysis
7.3.1 Branded
7.3.2 Generic
7.4 Sales Analysis
8. NILOTINIB – 2ND GENERATION BCR-ABL INHIBITOR 2007
8.1 Overview
8.2 Patent & Exclusivity
8.3 Price & Dosage Analysis
8.4 Sales Analysis
9. BOSUTINIB – 2ND GENERATION BCR-ABL INHIBITOR 2012
9.1 Overview
9.2 Patent & Exclusivity
9.3 Pricing & Dosage Analysis
9.4 Sales Analysis
10. PONATINIB – 3RD GENERATION BCR-ABL INHIBITOR 2012
10.1 Overview
10.2 Patent & Exclusivity
10.3 Pricing & Dosage Analysis
10.4 Sales Analysis
11. ASCIMINIB – 3RD GENERATION BCR-ABL INHIBITOR 2021
11.1 Overview
11.2 Patent & Exclusivity
11.3 Pricing & Dosage Analysis
12. OLVEREMBATINIB – 3RD GENERATION BCR-ABL INHIBITOR 2021
13. BCR-ABL INHIBITORS SALES FORECAST 2022 TILL 2028
13.1 Gleevec/Glivec Sales Forecast
13.2 Sprycel Sales Forecast
13.3 Tasigna Sales Forecast
13.4 Bosulif Sales Forecast
13.5 Iclusig Sales Forecast
14. BCR-ABL INHIBITOR MARKET CLINICAL TRIAL INSIGHTS
14.1 By Indication
14.2 By Organization
14.3 By Patient Segment
14.4 By Phase
14.5 By Status
14.6 By Region
15. GLOBAL BCR-ABL TYROSINE KINASE INHIBITORS CLINICAL TRIALS INSIGHT BY COMPANY, INDICATION & PHASE
15.1 Preclinical
15.2 Clinical
15.3 Phase-I
15.4 Phase-I/II
15.5 Phase-II
15.6 Phase-II/III
15.7 Registered
16. MARKETED BCR-ABL INHIBITORS CLINICAL TRIALS INSIGHT
17. BCR-ABL INHIBITORS MARKET DYNAMICS
17.1 Market Favorable Parameters
17.2 Market Challenges
18. BCR-ABL INHIBITOR MARKET FUTURE PERSPECTIVE
19. COMPETITIVE LANDSCAPE
19.1 Ascentage Pharma
19.2 AstraZeneca
19.3 Bristol Myers Squibb
19.4 Fusion Pharmaceuticals
19.5 Incyte Pharmaceutical
19.6 Merck
19.7 Novartis
19.8 Pfizer
19.9 Takeda Pharmaceuticals
19.10 Teva Pharmaceutical
LIST OF FIGURES
Figure 1-1: Therapeutic Options for Management of CML
Figure 1-2: Evolution of Bcr-Abl Inhibitors Development
Figure 2-1: Imatinib – Mechanism of Action in CML
Figure 2-2: Pathways Regulated by Bcr-Abl in Cancer
Figure 3-1: Global – Leukemia Incidences & Death, 2020 & 2025
Figure 3-2: Bcr-Abl Inhibitor - Drugs Sales (US$ Million), 2021
Figure 3-3: Bcr-Abl Inhibitor - Drugs Sales (US$ Million), 2020
Figure 3-4: Bcr-Abl Inhibitor - Drugs Sales (US$ Million), 2019
Figure 3-5: Bcr-Abl Inhibitor - Drugs Sales (US$ Million), 2018
Figure 3-6: Bcr-Abl Inhibitor - Drugs Market by Region (US$ Billion), 2021
Figure 3-7: Bcr-Abl Inhibitor - Drugs Market by Region (%), 2021
Figure 3-8: Global – Bcr-Abl Inhibitors Drugs Market Size (US$ Billion), 2022 - 2028
Figure 4-1: US – Leukemia Incidences & Death, 2020 & 2025
Figure 4-2: US vs. ROW - Bcr-Abl Inhibitor Drugs Market (US$ Billion), 2021
Figure 4-3: US vs. ROW - Bcr-Abl Inhibitor Drugs Market (%), 2021
Figure 4-4: US – Bcr-Abl Inhibitors Drugs Market Size (US$ Billion), 2022 - 2028
Figure 4-5: Europe – Leukemia Incidences & Death, 2020 & 2025
Figure 4-6: Europe vs. ROW - Bcr-Abl Inhibitor Drugs Market (US$ Billion), 2021
Figure 4-7: Europe vs. ROW - Bcr-Abl Inhibitor Drugs Market (%), 2021
Figure 4-8: Europe – Bcr-Abl Inhibitors Drugs Market Size (US$ Million), 2022 - 2028
Figure 4-9: Japan – Leukemia Incidences & Death, 2020 & 2025
Figure 4-10: Japan vs. ROW - Bcr-Abl Inhibitor Drugs Market (US$ Billion), 2021
Figure 4-11: Japan vs. ROW - Bcr-Abl Inhibitor Drugs Market (%), 2021
Figure 4-12: Japan – Bcr-Abl Inhibitors Drugs Market Size (US$ Million), 2022 – 2028
Figure 4-13: China – Leukemia Incidences & Death, 2020 & 2025
Figure 4-14: India – Leukemia Incidences & Death, 2020 & 2025
Figure 4-15: ROW – Bcr-Abl Inhibitors Drugs Market Size (US$ Million), 2021 - 2028
Figure 4-16: China – Bcr-Abl Inhibitors Drugs Market Size (US$ Million), 2021 - 2028
Figure 5-1: First Generation vs. Others – Bcr-Abl Inhibitor Drugs Market (%), 2021
Figure 5-2: First Generation vs. Others – Bcr-Abl Inhibitor Drugs Market (%), 2021
Figure 5-3: Global - First Generation Bcr-Abl Inhibitor Drugs Market Size (US$ Million), 2022 - 2028
Figure 5-4: Second Generation vs. Others – Bcr-Abl Inhibitor Drugs Market (%), 2021
Figure 5-5: Second Generation vs. Others – Bcr-Abl Inhibitor Drugs Market (%), 2021
Figure 5-6: Second Generation Bcr-Abl Inhibitor Drugs Market by Drug Type (%), 2021
Figure 5-7: Second Generation Bcr-Abl Inhibitor Drugs Market by Drug Type (US$ Million), 2021
Figure 5-8: Global - Second Generation Bcr-Abl Inhibitor Drugs Market Size (US$ Million), 2022 - 2028
Figure 5-9: Third Generation vs. Others – Bcr-Abl Inhibitor Drugs Market (%), 2021
Figure 5-10: Third Generation vs. Others – Bcr-Abl Inhibitor Drugs Market (%), 2021
Figure 5-11: Global - Third Generation Bcr-Abl Inhibitor Drugs Market Size (US$ Million), 2022 - 2028
Figure 6-1: US – Imatinib FDA Orphan Drug Designation by Indication
Figure 6-2: Imatinib – Approval Year by Region
Figure 6-3: US – Gleevec FDA Approval History by Indication
Figure 6-4: US – Gleevec Patent Approval & Expiration Year
Figure 6-5: Imatinib – Ist Generic Approval by Region
Figure 6-6: US – Cost of Supply of 90 Tablets & Per Unit Cost of Gleevec 100mg (US$), March’2022
Figure 6-7: US – Cost of Supply of 30 Tablets & Per Unit Cost of Gleevec 400mg (US$), March’2022
Figure 6-8: UK – Cost of Supply of 60 Tablets & Per Unit Cost of Glivec 100mg (GBP/US$), March’2022
Figure 6-9: UK – Cost of Supply of 30 Tablets & Per Unit Cost of Glivec 400mg (GBP/US$), March’2022
Figure 6-10: US – Cost of Supply of 20 Tablets & Per Unit Cost of Imatinib 100mg (US$), March’2022
Figure 6-11: US – Cost of Supply of 30 Tablets & Per Unit Cost of Imatinib 100mg (US$), March’2022
Figure 6-12: US – Cost of Supply of 90 Tablets & Per Unit Cost of Imatinib 100mg (US$), March’2022
Figure 6-13: US – Cost of Supply of 20 Tablets & Per Unit Cost of Imatinib 400mg (US$), March’2022
Figure 6-14: US – Cost of Supply of 30 Tablets & Per Unit Cost of Imatinib 400mg (US$), March’2022
Figure 6-15: UK – Cost of Supply of 60 Tablets & Per Unit Cost of Imatinib 100mg (GBP/US$), March’2022
Figure 6-16: UK – Cost of Supply of 30 Tablets & Per Unit Cost of Glivec 400mg (GBP/US$), March’2022
Figure 6-17: Imatinib – Recommended Initial Dose in Adult by Therapeutic Condition (mg/day)
Figure 6-18: Global - Gleevec/Glivec Annual Sales (US$ Million), 2018-2021
Figure 6-19: Global - Gleevec/Glivec Quarterly Sales (US$ Million), 2021
Figure 6-20: Global - Gleevec/Glivec Quarterly Sales (US$ Million), 2019 & 2020
Figure 7-1: US - Sprycel Orphan Drug Designation Approval & Exclusivity for CML
Figure 7-2: US - Sprycel Orphan Drug Designation Approval & Exclusivity for Ph+ ALL
Figure 7-3: US - Sprycel Orphan Drug Designation & FDA Approval Year
Figure 7-4: Sprycel – Approval Year by Region
Figure 7-5: US – Sprycel Approval Year by Indication
Figure 7-6: US – Sprycel Patent Approval & Expiration Year
Figure 7-7: Japan – Sprycel Approval & Patent Exclusivity Year
Figure 7-8: Europe – Branded & 1st Generic Approval Year
Figure 7-9: US – Cost of Supply of 60 Tablets & Per Unit Cost of Sprycel 20mg (US$), March’2022
Figure 7-10: US – Cost of Supply of 60 Tablets & Per Unit Cost of Sprycel 50mg & 70mg (US$), March’2022
Figure 7-11: US – Cost of Supply of 60 Tablets & Per Unit Cost of Sprycel 80mg, 100mg & 140mg (US$), March’2022
Figure 7-12: UK – Cost of Supply of 60 Tablets & Per Unit Cost of Sprycel 20mg (GBP/US$), March’2022
Figure 7-13: UK – Cost of Supply of 30 Tablets & Per Unit Cost of Sprycel 50mg, 80mg, 100mg & 140mg (GBP/US$), March’2022
Figure 7-14: UK – Cost of Supply of 60 Tablets & Per Unit Cost of Sprycel 20mg (GBP/US$), March’2022
Figure 7-15: UK – Cost of Supply of 30 Tablets & Per Unit Cost of Sprycel 50mg, 80mg, 100mg & 140mg (GBP/US$), March’2022
Figure 7-16: Dasatinib – Initial Recommended Dose by Indication for Adults (mg/day)
Figure 7-17: Dasatinib – Initial Recommended Dose by Indication for Pediatric Patients by Weight (mg/day)
Figure 7-18: Global - Sprycel Annual Sales (US$ Million), 2017-2021
Figure 7-19: US - Sprycel Annual Sales (US$ Million), 2017-2021
Figure 7-20: Sprycel – Annual Sales by Region (US$ Million), 2021
Figure 7-21: Sprycel – Annual Sales by Region (%), 2021
Figure 7-22: Sprycel – Annual Sales by Region (%), 2020
Figure 7-23: Global - Sprycel Quarterly Sales (US$ Million), 2021
Figure 7-24: US - Sprycel Quarterly Sales (US$ Million), 2021
Figure 7-25: Global - Sprycel Quarterly Sales (US$ Million), 2020
Figure 7-26: US - Sprycel Quarterly Sales (US$ Million), 2020
Figure 8-1: US - Tasgina Orphan Drug Designation Approval & Exclusivity for CML
Figure 8-2: Tasigna – Approval Year by Region
Figure 8-3: US - Tasigna Orphan Drug Designation & Approval Year
Figure 8-4: Europe - Tasigna Orphan Drug Designation & Approval Year
Figure 8-5: US – Tasigna Approval History by Indication
Figure 8-6: US – Tasigna Patent Approval & Expiration Year
Figure 8-7: Canada – Tasigna Patent Approval & Expiration Year
Figure 8-8: US – Tasigna FDA Approval & Patent Exclusivity Year
Figure 8-9: Europe – Tasigna EMA Approval & Patent Exclusivity Year
Figure 8-10: US – Cost of Supply of 120 Capsules & Per Unit Cost of Tasigna 50mg (US$), March’2022
Figure 8-11: US – Cost of Supply of 28 Capsules & Per Unit Cost of Tasigna 150mg & 200mg (US$), March’2022
Figure 8-12: US – Cost of Supply of 112 Capsules & Per Unit Cost of Tasigna1500mg & 200mg (US$), March’2022
Figure 8-13: UK – Cost of Supply of 120 Capsules & Per Unit Cost of Tasigna 50mg (GBP/US$), March’2022
Figure 8-14: UK – Cost of Supply of 112 Capsules & Per Unit Cost of Tasigna 150mg & 200mg (GBP/US$), March’2022
Figure 8-15: Nilotinib – Initial Recommended Dose by Indication (mg/day)
Figure 8-16: Nilotinib – Minimum & Maximum Recommended Dose in Pediatric CML (mg/day)
Figure 8-17: Global - Tasigna Annual Sales (US$ Million), 2018-2021
Figure 8-18: Global - Tasigna Quarterly Sales (US$ Million), 2021
Figure 8-19: Global - Tasigna Quarterly Sales (US$ Million), 2019 & 2020
Figure 9-1: US - Bosulif Orphan Drug Designation Approval & Exclusivity for CML
Figure 9-2: Bosulif – Approval Year by Region
Figure 9-3: US - Bosulif Orphan Drug Designation & Approval Year
Figure 9-4: US - Bosulif Approval by Indication
Figure 9-5: US – Bosulif Patent Approval & Expiration Year
Figure 9-6: Europe – Bosutif EMA Approval & Patent Exclusivity Year
Figure 9-7: US – Cost of Supply of 120 Tablets & Per Unit Cost of Bosulif 100mg (US$), March’2022
Figure 9-8: US – Cost of Supply of 120 Tablets & Per Unit Cost of Bosulif 400mg & 500mg (US$), March’2022
Figure 9-9: UK – Cost of Supply of 28 Tablets & Per Unit Cost of Basulif 100mg (GBP/US$), March’2022
Figure 9-10: UK – Cost of Supply of 28 Tablets & Per Unit Cost of Basulif 400mg & 500mg (GBP/US$), March’2022
Figure 9-11: Bosutinib – Initial Recommended Dose by Indication for Adults (mg/day)
Figure 9-12: Bosutinib – Minimum & Maximum Recommended Dose (mg/day)
Figure 9-13: Global - Bosulif Annual Sales (US$ Million), 2017-2021
Figure 9-14: US - Bosulif Annual Sales (US$ Million), 2017-2021
Figure 9-15: Europe - Bosulif Annual Sales (US$ Million), 2017-2021
Figure 9-16: Bosulif – Annual Sales by Region (US$ Million), 2021
Figure 9-17: Bosulif – Annual Sales by Region (%), 2021
Figure 9-18: Bosulif – Annual Sales by Region (%), 2020
Figure 9-19: Global - Bolusif Quarterly Sales (US$ Million), 2021
Figure 9-20: US - Bolusif Quarterly Sales (US$ Million), 2021
Figure 9-21: Europe - Bolusif Quarterly Sales (US$ Million), 2021
Figure 9-22: Global - Bosulif Quarterly Sales (US$ Million), 2020
Figure 9-23: US - Bosulif Quarterly Sales (US$ Million), 2020
Figure 10-1: Iclusig - Orphan Drug Designation by Region
Figure 10-2: US - Iclusig Orphan Drug Designation & Approval Year
Figure 10-3: Europe - Iclusig Orphan Drug Designation & Approval Year
Figure 10-4: Iclusig – Approval Year by Region
Figure 10-5: US – Iclusig Approval by Indication
Figure 10-6: US – Iclusig Patent Approval & Expiration Year
Figure 10-7: Europe – Iclusig EMA Approval & Patent Exclusivity Year
Figure 10-8: Japan – Iclusig Approval & Patent Exclusivity Year
Figure 10-9: US – Cost of Supply of 30 Tablets & Per Unit Cost of Iclusig Oral Tablet (US$), March’2022
Figure 10-10: UK – Cost of Supply of 30 Tablets & Per Unit Cost of Iclusig 15mg (GBP/US$), March’2022
Figure 10-11: UK – Cost of Supply of 30 Tablets & Per Unit Cost of Iclusig 30mg & 45mg (GBP/US$), March’2022
Figure 10-12: Ponatinib – Initial & Dose Reductions for CP-CML (mg/day)
Figure 10-13: Ponatinib – Initial & Dose Reductions for Resistant CML & Ph+ ALL (mg/day)
Figure 10-14: Global - Inclusig Annual Sales (US$ Million), 2017-2021
Figure 10-15: Global - Inclusig Quarterly Sales (US$ Million), 2021
Figure 10-16: Global - Inclusig Quarterly Sales (US$ Million), 2019 & 2020
Figure 11-1: US - Scemblix Orphan Drug Designation & Approval Year
Figure 11-2: US – Scemblix Patent Issue & Expiration Year
Figure 11-3: US – Scemblix FDA Approval & Patent Exclusivity Year
Figure 11-4: US – Cost of Supply of 60 Tablets & Per Unit Cost of Scemblix Oral Tablet (US$), March’2022
Figure 11-5: Scemblix – Initial & Dose Reductions for Ph+ CML-CP, Previously Treated with Two or More TKIs (mg/day)
Figure 11-6: Scemblix – Initial & Dose Reductions for Ph+ CML-CP with the T315I Mutation (mg/day)
Figure 12-1: China – Olverembatinib Priority Review, Breakthrough Therapy Designation & NMPA Approval Year
Figure 12-2: Olverembatinib – Orphan Designation by Region
Figure 13-1: Global - Glivec/Gleevec Sales Forecast (US$ Million), 2022 - 2028
Figure 13-2: Global - Sprycel Sales Forecast (US$ Million), 2022 - 2028
Figure 13-3: US - Sprycel Sales Forecast (US$ Million), 2022 - 2028
Figure 13-4: ROW - Sprycel Sales Forecast (US$ Million), 2022 - 2028
Figure 13-5: Global - Tasigna Sales Forecast (US$ Million), 2022 - 2028
Figure 13-6: Global – Bolusif Sales Forecast (US$ Million), 2022 – 2028
Figure 13-7: US – Bolusif Sales Forecast (US$ Million), 2022 – 2028
Figure 13-8: Europe – Bolusif Sales Forecast (US$ Million), 2022 – 2028
Figure 13-9: ROW – Bolusif Sales Forecast (US$ Million), 2022 – 2028
Figure 13-10: Global – Iclusig Sales Forecast (US$ Million), 2022 - 2028
Figure 14-1: BCR-ABL Inhibitor - Number of Drugs in Clinical Trials by Indication, April’2022
Figure 14-2: BCR-ABL Inhibitor - Number of Drugs in Clinical Trials by organization, April’2022
Figure 14-3: BCR-ABL Inhibitor - Number of Drugs in Clinical Trials by Patient Segment, April’2022
Figure 14-4: BCR-ABL Inhibitor - Number of Drugs in Clinical Trials by Phase, April’2022
Figure 14-5: BCR-ABL Inhibitor - Number of Clinical Trials by Status, March’2022
Figure 14-6: BCR-ABL Inhibitor - Number of Clinical Trials by Region, March’2022
Figure 14-7: North America – Bcr-Abl Inhibitors Number of Clinical Trial by Countries, March’2022
Figure 17-1: Bcr-Abl Inhibitor Market – Favorable Parameters
Figure 17-2: BCR-ABL Inhibitor Market Challenges
Figure 1-1: Therapeutic Options for Management of CML
Figure 1-2: Evolution of Bcr-Abl Inhibitors Development
Figure 2-1: Imatinib – Mechanism of Action in CML
Figure 2-2: Pathways Regulated by Bcr-Abl in Cancer
Figure 3-1: Global – Leukemia Incidences & Death, 2020 & 2025
Figure 3-2: Bcr-Abl Inhibitor - Drugs Sales (US$ Million), 2021
Figure 3-3: Bcr-Abl Inhibitor - Drugs Sales (US$ Million), 2020
Figure 3-4: Bcr-Abl Inhibitor - Drugs Sales (US$ Million), 2019
Figure 3-5: Bcr-Abl Inhibitor - Drugs Sales (US$ Million), 2018
Figure 3-6: Bcr-Abl Inhibitor - Drugs Market by Region (US$ Billion), 2021
Figure 3-7: Bcr-Abl Inhibitor - Drugs Market by Region (%), 2021
Figure 3-8: Global – Bcr-Abl Inhibitors Drugs Market Size (US$ Billion), 2022 - 2028
Figure 4-1: US – Leukemia Incidences & Death, 2020 & 2025
Figure 4-2: US vs. ROW - Bcr-Abl Inhibitor Drugs Market (US$ Billion), 2021
Figure 4-3: US vs. ROW - Bcr-Abl Inhibitor Drugs Market (%), 2021
Figure 4-4: US – Bcr-Abl Inhibitors Drugs Market Size (US$ Billion), 2022 - 2028
Figure 4-5: Europe – Leukemia Incidences & Death, 2020 & 2025
Figure 4-6: Europe vs. ROW - Bcr-Abl Inhibitor Drugs Market (US$ Billion), 2021
Figure 4-7: Europe vs. ROW - Bcr-Abl Inhibitor Drugs Market (%), 2021
Figure 4-8: Europe – Bcr-Abl Inhibitors Drugs Market Size (US$ Million), 2022 - 2028
Figure 4-9: Japan – Leukemia Incidences & Death, 2020 & 2025
Figure 4-10: Japan vs. ROW - Bcr-Abl Inhibitor Drugs Market (US$ Billion), 2021
Figure 4-11: Japan vs. ROW - Bcr-Abl Inhibitor Drugs Market (%), 2021
Figure 4-12: Japan – Bcr-Abl Inhibitors Drugs Market Size (US$ Million), 2022 – 2028
Figure 4-13: China – Leukemia Incidences & Death, 2020 & 2025
Figure 4-14: India – Leukemia Incidences & Death, 2020 & 2025
Figure 4-15: ROW – Bcr-Abl Inhibitors Drugs Market Size (US$ Million), 2021 - 2028
Figure 4-16: China – Bcr-Abl Inhibitors Drugs Market Size (US$ Million), 2021 - 2028
Figure 5-1: First Generation vs. Others – Bcr-Abl Inhibitor Drugs Market (%), 2021
Figure 5-2: First Generation vs. Others – Bcr-Abl Inhibitor Drugs Market (%), 2021
Figure 5-3: Global - First Generation Bcr-Abl Inhibitor Drugs Market Size (US$ Million), 2022 - 2028
Figure 5-4: Second Generation vs. Others – Bcr-Abl Inhibitor Drugs Market (%), 2021
Figure 5-5: Second Generation vs. Others – Bcr-Abl Inhibitor Drugs Market (%), 2021
Figure 5-6: Second Generation Bcr-Abl Inhibitor Drugs Market by Drug Type (%), 2021
Figure 5-7: Second Generation Bcr-Abl Inhibitor Drugs Market by Drug Type (US$ Million), 2021
Figure 5-8: Global - Second Generation Bcr-Abl Inhibitor Drugs Market Size (US$ Million), 2022 - 2028
Figure 5-9: Third Generation vs. Others – Bcr-Abl Inhibitor Drugs Market (%), 2021
Figure 5-10: Third Generation vs. Others – Bcr-Abl Inhibitor Drugs Market (%), 2021
Figure 5-11: Global - Third Generation Bcr-Abl Inhibitor Drugs Market Size (US$ Million), 2022 - 2028
Figure 6-1: US – Imatinib FDA Orphan Drug Designation by Indication
Figure 6-2: Imatinib – Approval Year by Region
Figure 6-3: US – Gleevec FDA Approval History by Indication
Figure 6-4: US – Gleevec Patent Approval & Expiration Year
Figure 6-5: Imatinib – Ist Generic Approval by Region
Figure 6-6: US – Cost of Supply of 90 Tablets & Per Unit Cost of Gleevec 100mg (US$), March’2022
Figure 6-7: US – Cost of Supply of 30 Tablets & Per Unit Cost of Gleevec 400mg (US$), March’2022
Figure 6-8: UK – Cost of Supply of 60 Tablets & Per Unit Cost of Glivec 100mg (GBP/US$), March’2022
Figure 6-9: UK – Cost of Supply of 30 Tablets & Per Unit Cost of Glivec 400mg (GBP/US$), March’2022
Figure 6-10: US – Cost of Supply of 20 Tablets & Per Unit Cost of Imatinib 100mg (US$), March’2022
Figure 6-11: US – Cost of Supply of 30 Tablets & Per Unit Cost of Imatinib 100mg (US$), March’2022
Figure 6-12: US – Cost of Supply of 90 Tablets & Per Unit Cost of Imatinib 100mg (US$), March’2022
Figure 6-13: US – Cost of Supply of 20 Tablets & Per Unit Cost of Imatinib 400mg (US$), March’2022
Figure 6-14: US – Cost of Supply of 30 Tablets & Per Unit Cost of Imatinib 400mg (US$), March’2022
Figure 6-15: UK – Cost of Supply of 60 Tablets & Per Unit Cost of Imatinib 100mg (GBP/US$), March’2022
Figure 6-16: UK – Cost of Supply of 30 Tablets & Per Unit Cost of Glivec 400mg (GBP/US$), March’2022
Figure 6-17: Imatinib – Recommended Initial Dose in Adult by Therapeutic Condition (mg/day)
Figure 6-18: Global - Gleevec/Glivec Annual Sales (US$ Million), 2018-2021
Figure 6-19: Global - Gleevec/Glivec Quarterly Sales (US$ Million), 2021
Figure 6-20: Global - Gleevec/Glivec Quarterly Sales (US$ Million), 2019 & 2020
Figure 7-1: US - Sprycel Orphan Drug Designation Approval & Exclusivity for CML
Figure 7-2: US - Sprycel Orphan Drug Designation Approval & Exclusivity for Ph+ ALL
Figure 7-3: US - Sprycel Orphan Drug Designation & FDA Approval Year
Figure 7-4: Sprycel – Approval Year by Region
Figure 7-5: US – Sprycel Approval Year by Indication
Figure 7-6: US – Sprycel Patent Approval & Expiration Year
Figure 7-7: Japan – Sprycel Approval & Patent Exclusivity Year
Figure 7-8: Europe – Branded & 1st Generic Approval Year
Figure 7-9: US – Cost of Supply of 60 Tablets & Per Unit Cost of Sprycel 20mg (US$), March’2022
Figure 7-10: US – Cost of Supply of 60 Tablets & Per Unit Cost of Sprycel 50mg & 70mg (US$), March’2022
Figure 7-11: US – Cost of Supply of 60 Tablets & Per Unit Cost of Sprycel 80mg, 100mg & 140mg (US$), March’2022
Figure 7-12: UK – Cost of Supply of 60 Tablets & Per Unit Cost of Sprycel 20mg (GBP/US$), March’2022
Figure 7-13: UK – Cost of Supply of 30 Tablets & Per Unit Cost of Sprycel 50mg, 80mg, 100mg & 140mg (GBP/US$), March’2022
Figure 7-14: UK – Cost of Supply of 60 Tablets & Per Unit Cost of Sprycel 20mg (GBP/US$), March’2022
Figure 7-15: UK – Cost of Supply of 30 Tablets & Per Unit Cost of Sprycel 50mg, 80mg, 100mg & 140mg (GBP/US$), March’2022
Figure 7-16: Dasatinib – Initial Recommended Dose by Indication for Adults (mg/day)
Figure 7-17: Dasatinib – Initial Recommended Dose by Indication for Pediatric Patients by Weight (mg/day)
Figure 7-18: Global - Sprycel Annual Sales (US$ Million), 2017-2021
Figure 7-19: US - Sprycel Annual Sales (US$ Million), 2017-2021
Figure 7-20: Sprycel – Annual Sales by Region (US$ Million), 2021
Figure 7-21: Sprycel – Annual Sales by Region (%), 2021
Figure 7-22: Sprycel – Annual Sales by Region (%), 2020
Figure 7-23: Global - Sprycel Quarterly Sales (US$ Million), 2021
Figure 7-24: US - Sprycel Quarterly Sales (US$ Million), 2021
Figure 7-25: Global - Sprycel Quarterly Sales (US$ Million), 2020
Figure 7-26: US - Sprycel Quarterly Sales (US$ Million), 2020
Figure 8-1: US - Tasgina Orphan Drug Designation Approval & Exclusivity for CML
Figure 8-2: Tasigna – Approval Year by Region
Figure 8-3: US - Tasigna Orphan Drug Designation & Approval Year
Figure 8-4: Europe - Tasigna Orphan Drug Designation & Approval Year
Figure 8-5: US – Tasigna Approval History by Indication
Figure 8-6: US – Tasigna Patent Approval & Expiration Year
Figure 8-7: Canada – Tasigna Patent Approval & Expiration Year
Figure 8-8: US – Tasigna FDA Approval & Patent Exclusivity Year
Figure 8-9: Europe – Tasigna EMA Approval & Patent Exclusivity Year
Figure 8-10: US – Cost of Supply of 120 Capsules & Per Unit Cost of Tasigna 50mg (US$), March’2022
Figure 8-11: US – Cost of Supply of 28 Capsules & Per Unit Cost of Tasigna 150mg & 200mg (US$), March’2022
Figure 8-12: US – Cost of Supply of 112 Capsules & Per Unit Cost of Tasigna1500mg & 200mg (US$), March’2022
Figure 8-13: UK – Cost of Supply of 120 Capsules & Per Unit Cost of Tasigna 50mg (GBP/US$), March’2022
Figure 8-14: UK – Cost of Supply of 112 Capsules & Per Unit Cost of Tasigna 150mg & 200mg (GBP/US$), March’2022
Figure 8-15: Nilotinib – Initial Recommended Dose by Indication (mg/day)
Figure 8-16: Nilotinib – Minimum & Maximum Recommended Dose in Pediatric CML (mg/day)
Figure 8-17: Global - Tasigna Annual Sales (US$ Million), 2018-2021
Figure 8-18: Global - Tasigna Quarterly Sales (US$ Million), 2021
Figure 8-19: Global - Tasigna Quarterly Sales (US$ Million), 2019 & 2020
Figure 9-1: US - Bosulif Orphan Drug Designation Approval & Exclusivity for CML
Figure 9-2: Bosulif – Approval Year by Region
Figure 9-3: US - Bosulif Orphan Drug Designation & Approval Year
Figure 9-4: US - Bosulif Approval by Indication
Figure 9-5: US – Bosulif Patent Approval & Expiration Year
Figure 9-6: Europe – Bosutif EMA Approval & Patent Exclusivity Year
Figure 9-7: US – Cost of Supply of 120 Tablets & Per Unit Cost of Bosulif 100mg (US$), March’2022
Figure 9-8: US – Cost of Supply of 120 Tablets & Per Unit Cost of Bosulif 400mg & 500mg (US$), March’2022
Figure 9-9: UK – Cost of Supply of 28 Tablets & Per Unit Cost of Basulif 100mg (GBP/US$), March’2022
Figure 9-10: UK – Cost of Supply of 28 Tablets & Per Unit Cost of Basulif 400mg & 500mg (GBP/US$), March’2022
Figure 9-11: Bosutinib – Initial Recommended Dose by Indication for Adults (mg/day)
Figure 9-12: Bosutinib – Minimum & Maximum Recommended Dose (mg/day)
Figure 9-13: Global - Bosulif Annual Sales (US$ Million), 2017-2021
Figure 9-14: US - Bosulif Annual Sales (US$ Million), 2017-2021
Figure 9-15: Europe - Bosulif Annual Sales (US$ Million), 2017-2021
Figure 9-16: Bosulif – Annual Sales by Region (US$ Million), 2021
Figure 9-17: Bosulif – Annual Sales by Region (%), 2021
Figure 9-18: Bosulif – Annual Sales by Region (%), 2020
Figure 9-19: Global - Bolusif Quarterly Sales (US$ Million), 2021
Figure 9-20: US - Bolusif Quarterly Sales (US$ Million), 2021
Figure 9-21: Europe - Bolusif Quarterly Sales (US$ Million), 2021
Figure 9-22: Global - Bosulif Quarterly Sales (US$ Million), 2020
Figure 9-23: US - Bosulif Quarterly Sales (US$ Million), 2020
Figure 10-1: Iclusig - Orphan Drug Designation by Region
Figure 10-2: US - Iclusig Orphan Drug Designation & Approval Year
Figure 10-3: Europe - Iclusig Orphan Drug Designation & Approval Year
Figure 10-4: Iclusig – Approval Year by Region
Figure 10-5: US – Iclusig Approval by Indication
Figure 10-6: US – Iclusig Patent Approval & Expiration Year
Figure 10-7: Europe – Iclusig EMA Approval & Patent Exclusivity Year
Figure 10-8: Japan – Iclusig Approval & Patent Exclusivity Year
Figure 10-9: US – Cost of Supply of 30 Tablets & Per Unit Cost of Iclusig Oral Tablet (US$), March’2022
Figure 10-10: UK – Cost of Supply of 30 Tablets & Per Unit Cost of Iclusig 15mg (GBP/US$), March’2022
Figure 10-11: UK – Cost of Supply of 30 Tablets & Per Unit Cost of Iclusig 30mg & 45mg (GBP/US$), March’2022
Figure 10-12: Ponatinib – Initial & Dose Reductions for CP-CML (mg/day)
Figure 10-13: Ponatinib – Initial & Dose Reductions for Resistant CML & Ph+ ALL (mg/day)
Figure 10-14: Global - Inclusig Annual Sales (US$ Million), 2017-2021
Figure 10-15: Global - Inclusig Quarterly Sales (US$ Million), 2021
Figure 10-16: Global - Inclusig Quarterly Sales (US$ Million), 2019 & 2020
Figure 11-1: US - Scemblix Orphan Drug Designation & Approval Year
Figure 11-2: US – Scemblix Patent Issue & Expiration Year
Figure 11-3: US – Scemblix FDA Approval & Patent Exclusivity Year
Figure 11-4: US – Cost of Supply of 60 Tablets & Per Unit Cost of Scemblix Oral Tablet (US$), March’2022
Figure 11-5: Scemblix – Initial & Dose Reductions for Ph+ CML-CP, Previously Treated with Two or More TKIs (mg/day)
Figure 11-6: Scemblix – Initial & Dose Reductions for Ph+ CML-CP with the T315I Mutation (mg/day)
Figure 12-1: China – Olverembatinib Priority Review, Breakthrough Therapy Designation & NMPA Approval Year
Figure 12-2: Olverembatinib – Orphan Designation by Region
Figure 13-1: Global - Glivec/Gleevec Sales Forecast (US$ Million), 2022 - 2028
Figure 13-2: Global - Sprycel Sales Forecast (US$ Million), 2022 - 2028
Figure 13-3: US - Sprycel Sales Forecast (US$ Million), 2022 - 2028
Figure 13-4: ROW - Sprycel Sales Forecast (US$ Million), 2022 - 2028
Figure 13-5: Global - Tasigna Sales Forecast (US$ Million), 2022 - 2028
Figure 13-6: Global – Bolusif Sales Forecast (US$ Million), 2022 – 2028
Figure 13-7: US – Bolusif Sales Forecast (US$ Million), 2022 – 2028
Figure 13-8: Europe – Bolusif Sales Forecast (US$ Million), 2022 – 2028
Figure 13-9: ROW – Bolusif Sales Forecast (US$ Million), 2022 – 2028
Figure 13-10: Global – Iclusig Sales Forecast (US$ Million), 2022 - 2028
Figure 14-1: BCR-ABL Inhibitor - Number of Drugs in Clinical Trials by Indication, April’2022
Figure 14-2: BCR-ABL Inhibitor - Number of Drugs in Clinical Trials by organization, April’2022
Figure 14-3: BCR-ABL Inhibitor - Number of Drugs in Clinical Trials by Patient Segment, April’2022
Figure 14-4: BCR-ABL Inhibitor - Number of Drugs in Clinical Trials by Phase, April’2022
Figure 14-5: BCR-ABL Inhibitor - Number of Clinical Trials by Status, March’2022
Figure 14-6: BCR-ABL Inhibitor - Number of Clinical Trials by Region, March’2022
Figure 14-7: North America – Bcr-Abl Inhibitors Number of Clinical Trial by Countries, March’2022
Figure 17-1: Bcr-Abl Inhibitor Market – Favorable Parameters
Figure 17-2: BCR-ABL Inhibitor Market Challenges
